Delayed
Canadian Securities Exchange
|
5-day change
|
1st Jan Change
|
- CAD
|
-.--%
|
|
-1.63%
|
+27.22%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
793.6
|
459
|
146.1
|
81.75
|
31.35
|
26.47
|
-
|
-
|
Enterprise Value (EV)
1 |
725.1
|
406.9
|
126.6
|
81.75
|
31.35
|
26.47
|
26.47
|
26.47
|
P/E ratio
|
-47.8
x
|
-8.66
x
|
-1.03
x
|
-1.35
x
|
-1.27
x
|
-0.89
x
|
-1.68
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.39
x
|
4.82
x
|
1.52
x
|
1.1
x
|
0.5
x
|
0.46
x
|
0.42
x
|
-
|
EV / Revenue
|
8.39
x
|
4.82
x
|
1.52
x
|
1.1
x
|
0.5
x
|
0.46
x
|
0.42
x
|
-
|
EV / EBITDA
|
-467
x
|
-22.7
x
|
-7.86
x
|
-6.91
x
|
-1.38
x
|
-1.58
x
|
-1.86
x
|
-2.24
x
|
EV / FCF
|
-16.4
x
|
-5.97
x
|
-4.24
x
|
-14.7
x
|
-1.64
x
|
-1.73
x
|
-10.4
x
|
-
|
FCF Yield
|
-6.12%
|
-16.7%
|
-23.6%
|
-6.83%
|
-60.9%
|
-57.7%
|
-9.63%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,03,781
|
1,39,520
|
1,44,324
|
1,51,848
|
1,53,924
|
1,57,228
|
-
|
-
|
Reference price
2 |
7.647
|
3.290
|
1.012
|
0.5384
|
0.2037
|
0.1683
|
0.1683
|
0.1683
|
Announcement Date
|
24/03/20
|
25/03/21
|
24/03/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
94.59
|
95.23
|
96.09
|
74.1
|
63.16
|
57.55
|
62.95
|
-
|
EBITDA
1 |
-1.7
|
-20.2
|
-18.6
|
-11.83
|
-22.67
|
-16.75
|
-14.2
|
-11.8
|
EBIT
1 |
-24.8
|
-52.47
|
-147.1
|
-18.21
|
-40.61
|
-28.4
|
-22.8
|
-
|
Operating Margin
|
-26.22%
|
-55.1%
|
-153.04%
|
-24.57%
|
-64.31%
|
-49.35%
|
-36.22%
|
-
|
Earnings before Tax (EBT)
1 |
-21.21
|
-40.87
|
-137.6
|
-59.22
|
-23.27
|
-29.7
|
-22.8
|
-
|
Net income
1 |
-15.57
|
-47.19
|
-137.7
|
-59.31
|
-23.8
|
-29.7
|
-16
|
-
|
Net margin
|
-16.46%
|
-49.55%
|
-143.32%
|
-80.04%
|
-37.68%
|
-51.61%
|
-25.42%
|
-
|
EPS
2 |
-0.1600
|
-0.3800
|
-0.9800
|
-0.4000
|
-0.1600
|
-0.1900
|
-0.1000
|
-
|
Free Cash Flow
1 |
-48.53
|
-76.85
|
-34.48
|
-5.58
|
-19.08
|
-15.26
|
-2.55
|
-
|
FCF margin
|
-51.3%
|
-80.7%
|
-35.88%
|
-7.53%
|
-30.21%
|
-26.53%
|
-4.05%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/03/20
|
25/03/21
|
24/03/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
24.83
|
19.36
|
18.88
|
17.04
|
18.9
|
17.01
|
16.01
|
14.29
|
15.84
|
12.12
|
13.42
|
13.59
|
16.9
|
14.6
|
15.2
|
EBITDA
1 |
-4.5
|
-5.25
|
-5.363
|
0.632
|
-4.503
|
-3.328
|
-7.136
|
-3.549
|
-6.501
|
-3.92
|
-3.633
|
-3.51
|
-2.7
|
-2.846
|
-2.84
|
EBIT
1 |
-118.6
|
-8.642
|
-7.938
|
-5.766
|
-6.099
|
-7.596
|
-10.71
|
-11.96
|
-10.35
|
-8.369
|
-7.1
|
-7
|
-6
|
-6.3
|
-5.6
|
Operating Margin
|
-477.62%
|
-44.65%
|
-42.05%
|
-33.84%
|
-32.27%
|
-44.66%
|
-66.91%
|
-83.67%
|
-65.3%
|
-69.03%
|
-52.9%
|
-51.52%
|
-35.5%
|
-43.15%
|
-36.84%
|
Earnings before Tax (EBT)
1 |
-117.4
|
-8.626
|
-7.87
|
-7.588
|
-35.14
|
-2.912
|
2.844
|
-15.14
|
-8.056
|
-9.618
|
-7.1
|
-7
|
-6
|
-6.3
|
-5.6
|
Net income
1 |
-117.5
|
-8.626
|
-7.87
|
-7.588
|
-35.23
|
-2.912
|
2.844
|
-15.14
|
-8.585
|
-9.634
|
-7.1
|
-7
|
-6
|
-6.3
|
-5.6
|
Net margin
|
-473.22%
|
-44.56%
|
-41.69%
|
-44.54%
|
-186.4%
|
-17.12%
|
17.77%
|
-105.94%
|
-54.18%
|
-79.46%
|
-52.9%
|
-51.52%
|
-35.5%
|
-43.15%
|
-36.84%
|
EPS
2 |
-0.8400
|
-0.0600
|
-0.0500
|
-0.0500
|
-0.2300
|
-0.0200
|
0.0200
|
-0.1000
|
-0.0600
|
-0.0600
|
-0.0500
|
-0.0400
|
-0.0400
|
-0.0400
|
-0.0300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/03/22
|
16/05/22
|
09/08/22
|
14/11/22
|
23/03/23
|
12/05/23
|
10/08/23
|
09/11/23
|
21/03/24
|
08/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
68.5
|
52
|
19.5
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-48.5
|
-76.8
|
-34.5
|
-5.58
|
-19.1
|
-15.3
|
-2.55
|
-
|
ROE (net income / shareholders' equity)
|
-10.1%
|
-15.6%
|
-18.4%
|
-76.5%
|
-35.8%
|
-74.2%
|
-214%
|
-
|
ROA (Net income/ Total Assets)
|
-6.98%
|
-17.7%
|
-14.7%
|
-31.6%
|
-14%
|
-18.8%
|
-20.8%
|
-
|
Assets
1 |
222.9
|
266.9
|
940.1
|
187.6
|
170.1
|
158
|
76.92
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
15.1
|
25.9
|
4.92
|
0.27
|
3.69
|
4.03
|
0.5
|
-
|
Capex / Sales
|
15.91%
|
27.2%
|
5.12%
|
0.36%
|
5.84%
|
7.01%
|
0.79%
|
-
|
Announcement Date
|
24/03/20
|
25/03/21
|
24/03/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
0.1683
USD Average target price
0.475
USD Spread / Average Target +182.15% Consensus |
1st Jan change
|
Capi.
|
---|
| +40.09% | 6.16B | | -16.34% | 4.46B | | -7.11% | 3.27B | | +5.14% | 3.2B | | -0.18% | 2.6B | | +47.93% | 1.98B | | -7.15% | 1.7B | | +0.67% | 1.66B | | -8.73% | 1.61B |
Alternative Medicine
|